AAP
RMD icon

Arax Advisory Partners’s ResMed RMD Stock Holding History

Arax Advisory Partners’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$73.2K Sell
326
-127
-28% -$31.6K ﹤0.01% 1525
2025
Q4 		$109K Buy
+453
New +$116K ﹤0.01% 1296
2025
Q3 		– Sell
-218
Closed -$62K – 4140
2025
Q2 		$62K Buy
218
+64
+42% +$15.3K ﹤0.01% 1141
2025
Q1 		$34.5K Sell
154
-20
-11% -$4.67K ﹤0.01% 1095
2024
Q4 		$39.8K Buy
174
+27
+18% +$6.5K ﹤0.01% 963
2024
Q3 		$35.9K Buy
147
+55
+60% +$12.3K ﹤0.01% 845
2024
Q2 		$17.6K Buy
92
+82
+820% +$16.6K ﹤0.01% 1018
2024
Q1 		$1.99K Sell
10
-12
-55% -$2.2K ﹤0.01% 1037
2023
Q4 		$3.79K Hold
22
– – ﹤0.01% 933
2023
Q3 		$3.25K Sell
22
-259
-92% -$46.8K ﹤0.01% 949
2023
Q2 		$61.5K Buy
281
+1
+0.4% +$223 0.01% 434
2023
Q1 		$61.3K Sell
280
-93
-25% -$20.2K 0.01% 426
2022
Q4 		$77.6K Sell
373
-20
-5% -$4.39K 0.01% 376
2022
Q3 		$86K Sell
393
-142
-27% -$32.3K 0.01% 333
2022
Q2 		$112K Sell
535
-10
-2% -$2.13K 0.02% 300
2022
Q1 		$132K Sell
545
-3
-0.5% -$726 0.02% 294
2021
Q4 		$143K Sell
548
-8
-1% -$2.08K 0.02% 282
2021
Q3 		$146K Sell
556
-19
-3% -$5.2K 0.02% 267
2021
Q2 		$142K Buy
+575
New +$121K 0.02% 274
2020
Q4 		$116K Buy
545
+17
+3% +$3.39K 0.02% 275
2020
Q3 		$90K Buy
528
+25
+5% +$4.62K 0.02% 284
2020
Q2 		$97K Sell
503
-4
-0.8% -$654 0.02% 265
2020
Q1 		$75K Sell
507
-51
-9% -$8.12K 0.02% 277
2019
Q4 		$86K Sell
558
-24
-4% -$3.46K 0.02% 266
2019
Q3 		$79K Buy
582
+1
+0.2% +$131 0.02% 266
2019
Q2 		$71K Buy
+581
New +$64.4K 0.02% 276

Other funds holding RMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Arax Advisory Partners's RMD Position: Q1 2026 in Review

Arax Advisory Partners reduced its ResMed (RMD) stake by 28% in Q1 2026, selling an estimated $31.6K and leaving 326 shares worth $73.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1525.

Arax Advisory Partners first reported a position in RMD in Q2 2019 and has held it in 26 quarters since. The position peaked at $146K in Q3 2021. 938 funds tracked by Wall St. Rank hold RMD as of Q1 2026.

  • Arax Advisory Partners held 326 shares of ResMed worth $73.2K as of Q1 2026.
  • Arax Advisory Partners sold 127 ResMed shares in Q1 2026, an estimated $31.6K.
  • ResMed made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #1525 holding.
  • Arax Advisory Partners first reported a position in ResMed in Q2 2019 and has held it in 26 quarters since.
  • Arax Advisory Partners's ResMed position peaked at $146K in Q3 2021.
  • 938 funds tracked by Wall St. Rank held ResMed as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.